Liver Patients International is a partner in the EU project GRIPonMASH.
GRIPonMASH will address the unmet public health need of reducing disease burden and comorbidities associated with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD).
GRIPonMASH is a consortium founded by Julius Clinical and the University Medical Center Utrecht consisting of 27 involved parties dedicated to bring about a transformational change in the detection and diagnosis of MASH patients. The four year project is funded by the Innovative Health Initiative Joint Undertaking (IHI) which is funded jointly by the European Union (represented by the European Commission) and the life science industries (represented by COCIR, EFPIA / Vaccines Europe, EuropaBio, MedTech Europe). The aim is to achieve better information, diagnosis and lifestyle advice on MASH.
Our goal is to increase the number of people diagnosed and aware of the lifestyle changes needed and decrease the number of people with MASH and liver cancer.